Tag: HIV
-
FDA Approves HIV Drug in Combination Treatment
The U.S. Food and Drug Administration approved today the drug Edurant (rilpivirine) as a treatment for HIV infection in adults, when used in combination with other antiretroviral drugs. Edurant is manufactured by Tibotec Therapeutics, a subsidiary of Johnson & Johnson, in Raritan, New Jersey. FDA approved the drug for the treatment of HIV-1 — the…
-
Math Techniques Developed to Aid HIV Drug Discovery
Researchers at Princeton University in New Jersey, and Johns Hopkins University School of Medicine in Baltimore, Maryland have developed mathematical methods for discovering new drugs for HIV and eventually for a range of diseases. Their results were published in a recent issue of Biophysical Journal. The new methods forecast the effectiveness of potential medicines by…
-
Study Shows Drug Combo Effective as HIV Prevention
A new study called iPrEx shows that individuals at high risk for HIV infection who took a once-a-day commercially-available tablet containing two widely used HIV medications experienced fewer HIV infections than those who received a placebo pill. The researchers say that the clinical trial, reported in the New England Journal of Medicine, is the first…
-
New iPhone App Offers HIV Drug Info
University of Liverpool in the U.K. has released an iPhone application (app), — HIV iChart — that provides access to information about drug interactions for both health care professionals and HIV patients. The HIV iChart app is based on the university’s HIV drug Web site that offers a comprehensive resource on potential drug interactions between…
-
NIH Awards $1.8 Million in Small Business Grants for Vaccines
Altravax Inc. in Fargo, North Dakota received two grants from National Institutes of Health (NIH) for research on vaccines for HIV-1. A third NIH grant supports the company’s work on vaccines for an influenza virus. All three grants, valued at $1.8 million, are awarded under NIH’s Small Business Innovation Research (SBIR) program. Two of the…
-
European Approval Sought for Daily HIV Treatment
Gilead Sciences Inc. of Foster City, California is seeking approval to market a combination of its Truvada drug with Tibotec Pharmaceuticals’ TMC278 as a single-dose daily treatment for HIV infection. If approved, the new single-tablet regimen would be only the second product that contains a complete antiretroviral treatment regimen in a single once-daily tablet, according…
-
Clinical Trial Shows Promise of Immune Therapy HIV Vaccine
Two researchers gave findings from a Phase II clinical trial, sponsored by FIT Biotech, a biotechnology company in Tampere, Finland, showing the company’s immunomodulator FIT-06 vaccine offered long-term reductions in viral load and statistically significant CD4 (white blood or T) cell count increases in HIV-infected, previously untreated patients. The effects lasted longer than two years…